913 related articles for article (PubMed ID: 33558752)
1. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
2. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
4. PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates.
Li Q; Li W; Xu K; Xing Y; Shi H; Jing Z; Li S; Hong Z
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546481
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ; Luo S; Twomey JD; Zhang B
MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
[TBL] [Abstract][Full Text] [Related]
8. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
[TBL] [Abstract][Full Text] [Related]
9. Advances with antibody-drug conjugates in breast cancer treatment.
Abdus Subhan M; Torchilin VP
Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
[TBL] [Abstract][Full Text] [Related]
10. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
Ascione L; Guidi L; Prakash A; Trapani D; LoRusso P; Lou E; Curigliano G
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431766. PubMed ID: 38828973
[TBL] [Abstract][Full Text] [Related]
12. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Jiang M; Li Q; Xu B
Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
[TBL] [Abstract][Full Text] [Related]
14. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
15. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
16. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
18. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]